SG10202004337WA - Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect - Google Patents

Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect

Info

Publication number
SG10202004337WA
SG10202004337WA SG10202004337WA SG10202004337WA SG10202004337WA SG 10202004337W A SG10202004337W A SG 10202004337WA SG 10202004337W A SG10202004337W A SG 10202004337WA SG 10202004337W A SG10202004337W A SG 10202004337WA SG 10202004337W A SG10202004337W A SG 10202004337WA
Authority
SG
Singapore
Prior art keywords
therapeutic
methods
botulinum toxin
long duration
cosmetic effect
Prior art date
Application number
SG10202004337WA
Other languages
English (en)
Inventor
Curtis L Ruegg
Jacob M Waugh
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58630886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10202004337W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of SG10202004337WA publication Critical patent/SG10202004337WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0059—Cosmetic or alloplastic implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
SG10202004337WA 2015-10-29 2016-10-28 Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect SG10202004337WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562248255P 2015-10-29 2015-10-29

Publications (1)

Publication Number Publication Date
SG10202004337WA true SG10202004337WA (en) 2020-06-29

Family

ID=58630886

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201803566TA SG11201803566TA (en) 2015-10-29 2016-10-28 Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
SG10202004337WA SG10202004337WA (en) 2015-10-29 2016-10-28 Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201803566TA SG11201803566TA (en) 2015-10-29 2016-10-28 Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect

Country Status (16)

Country Link
US (2) US20180311333A1 (ru)
EP (1) EP3368071B1 (ru)
JP (2) JP6955491B2 (ru)
KR (1) KR20180077202A (ru)
CN (1) CN109069608A (ru)
AU (2) AU2016343748A1 (ru)
BR (1) BR112018008684A2 (ru)
CA (1) CA3003447A1 (ru)
CO (1) CO2018005361A2 (ru)
DK (1) DK3368071T3 (ru)
ES (1) ES2907652T3 (ru)
IL (2) IL259016A (ru)
MX (1) MX2018005256A (ru)
RU (1) RU2018119765A (ru)
SG (2) SG11201803566TA (ru)
WO (1) WO2017075468A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007136616A (ru) * 2005-03-03 2009-04-10 Риванс Терапьютикс, Инк. (Us) Композиция и способ для местного применения и чрескожного введения ботулинового токсина
CN102869373B (zh) 2009-06-25 2017-05-10 雷文斯治疗公司 不含白蛋白的肉毒杆菌毒素制剂
PL2490986T3 (pl) * 2009-10-21 2019-03-29 Revance Therapeutics, Inc. Sposoby i systemy oczyszczania nieskompleksowanej neurotoksyny botulinowej
KR20180077202A (ko) 2015-10-29 2018-07-06 레반스 테라퓨틱스, 아이엔씨. 주사용 보툴리눔 독소 제제 및 긴 지속기간의 치료적 또는 미용적 효과를 갖는 이를 이용한 방법
JP2019535829A (ja) 2016-11-21 2019-12-12 エイリオン セラピューティクス， インコーポレイテッド 大型薬剤の経皮送達
CA3057302A1 (en) * 2017-03-22 2018-09-27 Bonti, Inc. Botulinum neurotoxins for use in therapy
JP2020520917A (ja) * 2017-05-18 2020-07-16 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 頸部ジストニアの治療方法
EP3641746A4 (en) 2017-06-19 2021-03-17 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIAL INFECTION
US20200390871A1 (en) * 2017-11-03 2020-12-17 Revance Therapeutics, Inc. Botulinum toxin formulations and methods of use thereof in plantar fascitis with extended duration of effect
WO2019113133A1 (en) * 2017-12-04 2019-06-13 Revance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
JP2022500417A (ja) * 2018-09-13 2022-01-04 アラーガン、インコーポレイテッドAllergan, Incorporated 咬筋肥大症の治療方法
EP3969038A1 (en) * 2019-05-14 2022-03-23 Eirion Therapeutics, Inc. Delaying peak effect and/or extending duration of response
US20230210963A1 (en) * 2020-03-18 2023-07-06 Revance Therapeutics, Inc. Injectable botulinum toxin methos for treating headaches
KR102397708B1 (ko) * 2020-04-29 2022-05-16 한국화학연구원 탄닌산을 포함하는 보툴리눔 독소 약제학적 조성물
KR102324855B1 (ko) * 2020-05-20 2021-11-11 오스템임플란트 주식회사 보툴리눔 독소를 포함하는 약제학적 액상 조성물
KR102266384B1 (ko) * 2021-01-25 2021-06-21 주식회사 울트라브이 필러용 생분해성 고분자 미세입자, 이를 포함한 필러용 동결건조체, 그 제조방법 및 상기 동결건조체를 포함하는 필러용 주사제
CN117561075A (zh) * 2021-04-26 2024-02-13 上海科技大学 肉毒杆菌神经毒素的肌内注射组合物
KR20230171400A (ko) * 2022-06-10 2023-12-20 (주)메디톡스 보툴리눔 독소 안정화 조성물, 이를 포함하는 보툴리눔 독소 제제 및 이에 사용하기 위한 폴리펩티드

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
DE60125986T3 (de) 2000-02-08 2011-07-28 Allergan, Inc., 92612, Calif. Pharmazeutische Zusammensetzungen mit Botulinum Toxin
DE10043982A1 (de) * 2000-09-05 2002-03-14 Armin Maurer Verfahren zur Verbesserung des Haarwuchses menschlichen Kopfhaares
SG10202100698QA (en) 2008-12-31 2021-02-25 Revance Therapeutics Inc Injectable Botulinum Toxin Formulations
CN102869373B (zh) 2009-06-25 2017-05-10 雷文斯治疗公司 不含白蛋白的肉毒杆菌毒素制剂
NO2661276T3 (ru) * 2011-01-07 2017-12-30
EP3103472A1 (en) 2012-03-22 2016-12-14 ReVance Therapeutics, Inc. Method of treatment of wrinkles using topical chemodenervating agents
WO2014066916A2 (en) * 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
KR20180077202A (ko) 2015-10-29 2018-07-06 레반스 테라퓨틱스, 아이엔씨. 주사용 보툴리눔 독소 제제 및 긴 지속기간의 치료적 또는 미용적 효과를 갖는 이를 이용한 방법

Also Published As

Publication number Publication date
RU2018119765A3 (ru) 2020-03-17
WO2017075468A1 (en) 2017-05-04
JP2022008814A (ja) 2022-01-14
IL259016A (en) 2018-06-28
JP6955491B2 (ja) 2021-10-27
RU2018119765A (ru) 2019-12-02
CO2018005361A2 (es) 2018-10-10
AU2016343748A1 (en) 2018-05-17
DK3368071T3 (da) 2022-05-02
MX2018005256A (es) 2019-09-04
EP3368071A1 (en) 2018-09-05
CN109069608A (zh) 2018-12-21
US20220062400A1 (en) 2022-03-03
KR20180077202A (ko) 2018-07-06
CA3003447A1 (en) 2017-05-04
US20180311333A1 (en) 2018-11-01
JP2018531984A (ja) 2018-11-01
EP3368071A4 (en) 2019-05-29
IL286472A (en) 2021-10-31
SG11201803566TA (en) 2018-05-30
AU2023241373A1 (en) 2023-10-26
BR112018008684A2 (pt) 2018-11-27
EP3368071B1 (en) 2022-01-26
ES2907652T3 (es) 2022-04-25

Similar Documents

Publication Publication Date Title
IL286472A (en) Injectable botulinum toxin formulations and methods of using them with a long-term medical or cosmetic effect
IL265590B (en) Formulations and methods for keratin treatment
IL259246A (en) Preparations containing pharmaceutical substances and methods of using them
IL275032A (en) Injectable botulinum toxin formulations and methods of using them with a high response rate and long duration of effect
IL256515A (en) Therapeutic peptides and methods of use thereof
FI3380525T3 (fi) Lääkeformulaatioita ja niiden käyttömenetelmiä
GB201519200D0 (en) Skin care composition and method thereof
IL282473A (en) A cosmetic method and the use of medicine to reduce fat
SG11201705524SA (en) Compositions and methods for the treatment of inflammation and pain
HK1259451A1 (zh) 護膚組合物及其方法
HK1258056A1 (zh) 治療性化合物和其使用方法
GB201511799D0 (en) Composition and methods of treatment
PT3503885T (pt) Composição farmacêutica e métodos de utilização
GB201611406D0 (en) Skin care composition and method thereof
GB201605127D0 (en) Composition and methods of treatment
HK1256840A1 (zh) 含有蛋白的外用皮膚組合物和使用方法
GB201611362D0 (en) Skin care composition and method thereof
GB201710491D0 (en) Composition and methods of treatment
EP3365079A4 (en) Therapeutic stick and method of use
GB201519207D0 (en) Skin care composition and method thereof
GB201508518D0 (en) Hair treatment compositions and methods